Experimental lovastatin myopathy.
Experimental lovastatin myopathy.
复制标题
实验性洛伐他汀肌病。
DOI:
10.1097/00005072-199309000-00012
复制
发表时间:
1993
影响因子:
3.2
通讯作者:
Engel,AG
中科院分区:
文献类型:
--
作者:
Waclawik,AJ;Lindal,S;Engel,AG
Lovastatin (LS) is a potent HMG-CoAinhibitor used in the treatment of hypercholesterolemia. In humans it can cause a severe, necrotizing myopathy with myoglobinuriaand renal failure. To investigate the pathogenesis of LS-induced myopathy we studied the effects of LS on rat skeletal muscle. Lewis rats were gavage-fed 1 mg/g body weight/day of LS. Control rats received carboxyrnethylcellulose-based suspension by gavage. Gastrocnemius and soleus, fast and slow twitch muscles respectively, were studied by light and electron microscopy. By day 10 LS-treated rats became severely weak. Gastrocnemius was severely affected with degeneration of membranous organelles and microvacuoleformation, but soleus was spared. Eventually, 20–50% of the gastrocnemius but none of the soleus fibers became necrotic. Non-necrotic fibers showed no increases of acid phosphatase, indicating that autophagy was not excited. We conclude that LS causes muscle injury by inducing degeneration of membranous organelles, and fast twitch muscle fibers are selectively vulnerable to LS myopathy.